Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced management will participate in three investor conference fireside chats in November–December 2025.

Schedule: Guggenheim Healthcare Innovation on Nov 11, 2025 at 8:30 AM ET; Piper Sandler Healthcare on Dec 2, 2025 at 2:00 PM ET; Evercore Healthcare on Dec 3, 2025 at 3:25 PM ET. Webcasts will be available on the company Events & Presentations page and accessible for replay for a limited time. Users are advised to connect several minutes early to ensure timely access to each live webcast.

BOULDER, Colo., Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences:

Guggenheim 2nd Annual Healthcare Innovation Conference
Fireside chat: Tuesday, November 11, 2025 at 8:30 am ET

Piper Sandler 37th Annual Healthcare Conference
Fireside chat: Tuesday, December 2, 2025 at 2 pm ET

8th Annual Evercore Healthcare Conference
Fireside chat: Wednesday, December 3, 2025 at 3:25 pm ET

The webcasts can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics                                                                                

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-participate-in-upcoming-investor-conferences-302607782.html

SOURCE Edgewise Therapeutics

FAQ

When will Edgewise Therapeutics (EWTX) present at the Guggenheim Healthcare Innovation Conference?

Edgewise management will present in a fireside chat on Nov 11, 2025 at 8:30 AM ET.

How can investors watch the Edgewise (EWTX) Piper Sandler conference presentation on Dec 2, 2025?

The Piper Sandler fireside chat on Dec 2, 2025 at 2:00 PM ET will be webcast on the company's Events & Presentations page.

Will the Edgewise (EWTX) Evercore Healthcare presentation on Dec 3, 2025 be available for replay?

Yes. The Dec 3, 2025 fireside chat webcast will be accessible for replay on the Events & Presentations page for a limited time.

What time should I join the live Edgewise (EWTX) webcasts to avoid connection issues?

It is recommended to connect several minutes prior to the scheduled start time to ensure a timely connection.

Where does Edgewise (EWTX) post links to its investor conference webcasts and replays?

Links and replays are posted on the company's Events & Presentations page on the investor relations website.